Myristoyl Pentapeptide-17
/ Synthetic myristoylated pentapeptide; INCI 'Myristoyl Pentapeptide-17'; eyelash growth cosmetic peptideALIAS · Myristoyl Pentapeptide-17 (INCI) · Eyelash growth peptide
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Cosmetic ingredient marketed in eyelash-growth and brow-conditioning formulations. Supplier dossiers describe keratin-gene upregulation in hair-follicle cultures as the proposed mechanism. PubMed-indexed peer-reviewed primary literature on this specific INCI is essentially absent.
The supplier-described mechanism is upregulation of keratin gene expression in hair-follicle keratinocytes, with claimed downstream effects on lash thickness, length, and density. Myristoylation at the N-terminus increases lipophilicity for topical delivery. Peer-reviewed independent mechanism characterisation is limited.
Tier 4. The published evidence is supplier-authored cosmetic-ingredient documentation and finished-product marketing studies; controlled clinical comparisons against bimatoprost (the FDA-approved prostaglandin-analog comparator in eyelash growth) are not in the peer-reviewed literature.
No published independent safety database. Cosmetic INCI status implies regulatory acceptance for topical periocular use in finished products; this is not equivalent to a clinical safety dataset.
Regulatory status
- FDA status:
- Not FDA-approved
The eyelash-growth cosmetic-peptide category competes commercially with the FDA-approved prescription product bimatoprost (Latisse), which has rigorous clinical-trial evidence. The cosmetic-peptide products in this category, including Myristoyl Pentapeptide-17, do not have comparable published evidence.